Overview To Compare the Efficacy and Safety of HRS9531 and Placebo in Subjects With Overweight or Obese Status: COMPLETED Trial end date: 2025-07-07 Target enrollment: Participant gender: Summary The study aims to evaluate the efficacy and safety of HRS9531 in subjects with overweight or obese for 48 weeks.Phase: PHASE3 Details Lead Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.